about
Translatability scoring in drug development: eight case studiesEmerging targeted therapies for melanoma treatment (review)Combining radiation and immunotherapy: a new systemic therapy for solid tumors?Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanomaImproved Survival with Ipilimumab in Patients with Metastatic MelanomaAugmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4Burden of illness for metastatic melanoma in Canada, 2011-2013Aldehyde dehydrogenase (ALDH) activity does not select for cells with enhanced aggressive properties in malignant melanomaMultiple metastatic malignant melanoma presenting intraluminal gallbladder bleeding.Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma.Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case reportIdentification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technologyClinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.Resource utilization and costs of managing patients with advanced melanoma: a Canadian population-based study.Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survivalA new understanding in the epidemiology of melanomaClinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience.Therapeutic options in cutaneous melanoma: latest developments.Cutaneous melanoma in situ: translational evidence from a large population-based studyPersonalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECISTPopulation-based estimates of survival and cost for metastatic melanoma.Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma.Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells.Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma.Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.Emerging options for the treatment of melanoma - focus on ipilimumab.Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft modelTargeting the RAS pathway in melanoma.Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.Ipilimumab for advanced melanoma: a pharmacologic perspective.Real-world impact of education: treating patients with ipilimumab in a community practice settingIpilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.Combination of targeted therapy and immunotherapy in melanoma.Ipilimumab: showing survival benefit in metastatic melanoma.Current management and novel agents for malignant melanoma.Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management.Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
P2860
Q22241760-6EFC5549-7F17-45A5-B1AD-6A8B29E321BBQ26829997-A915A71A-F697-4043-83E9-DC31BF062A38Q26991721-598DEEE7-B553-4EC7-B22F-0BA0DAE93B2FQ26996629-83D22E93-5954-4BA0-A29F-F8DEAAF09C49Q27861062-8879B901-8130-4723-BC24-58757EC6AF64Q28276508-D603825A-59D6-4DE3-81D1-1A093B129B68Q28354125-8381FE28-87CB-49CB-A459-2A3CE2B68ECFQ28474017-D2001511-AFCC-4B6C-BB3C-E69E5BCDA626Q30403800-D0EBFD1F-E2EC-4E24-879B-BE5E87B04B52Q33396455-3A78C673-3474-44BF-875C-C20DE4B33C2BQ33434066-1842344F-12ED-456E-9A39-5DEAEAB1CC20Q33608762-591A5436-1367-434E-A8B7-3C7EBB1F61DFQ33643902-9B66119B-14B8-4321-A81A-BB798C1C6EBFQ33783032-C1F62AE6-8EA5-4BA9-9C69-E93C8319BF14Q33840135-1E8D6E10-302B-4789-9233-1CD6E8D4E517Q34023444-ECF7E954-A74D-4A45-A61E-6B90D27D6258Q34625205-EE78DB02-74CF-4C55-BE33-2A46EAAC9232Q35196765-FF129E17-658A-4233-B292-32065D2C9DC8Q35205295-FA2F2162-DF2A-402B-8597-A1418094DB55Q35584985-46DFF945-D813-4D79-952C-994292DF4FF3Q36015295-4347E216-4312-4CFC-936B-8066DCF33AB8Q36169813-09A02DAD-1315-4790-8CDB-496A2EB5D677Q36283747-6110C395-ADAF-459B-83B7-CC2FD9C9694DQ36292634-76979C67-896C-4F56-87C1-E7C2A166C050Q36389325-14C63240-5E36-48A5-86F9-648358959F53Q36879912-4599811B-3EA5-4E57-B432-7B7F9078771EQ37003295-B20201F1-C7BC-411A-98BE-415F71F72025Q37031656-18D276DB-3C68-4766-8A33-D5C05903F25BQ37093432-C76B3D08-D04A-44F5-84FA-3243C070FA5FQ37137004-B34249D2-9AF8-4CF0-BCCC-9FCC71FBB383Q37182228-44CDF170-8D05-4897-AE4B-9EEB779D41BEQ37254169-5756D39D-30B3-4827-8B6F-760EF57D6D60Q37414993-F6AA1DFE-8795-44B0-93F7-16F03087D205Q37681718-98E7D799-9484-43E5-AD45-0ADDF175EB83Q37918893-060D600F-B870-4FFB-AF05-151ECC9FAED6Q37951602-694A943A-06B8-4AA5-A4FF-EDBE2CD681F3Q37983934-8905A02B-6417-4658-9F7A-809543689D4EQ38166382-ECC68D9E-7E70-4134-BE2E-0BFED93549F2Q38233339-1F335920-6622-453A-8D2F-CEFA502B30A7Q38516032-EE33B4CD-929A-47C3-BA91-5ACF872E6A37
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current systemic therapy for metastatic melanoma.
@en
Current systemic therapy for metastatic melanoma.
@nl
type
label
Current systemic therapy for metastatic melanoma.
@en
Current systemic therapy for metastatic melanoma.
@nl
prefLabel
Current systemic therapy for metastatic melanoma.
@en
Current systemic therapy for metastatic melanoma.
@nl
P2860
P356
P1476
Current systemic therapy for metastatic melanoma.
@en
P2093
Sanjiv S Agarwala
P2860
P304
P356
10.1586/ERA.09.25
P577
2009-05-01T00:00:00Z